PAVmed (NASDAQ:PAVM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

PAVmed Inc. (NASDAQ:PAVM) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $5.50 and traded as low as $4.89. PAVmed shares last traded at $5.20, with a volume of 9,380 shares changing hands.

Wall Street Analysts Forecast Growth

PAVM has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a report on Friday, July 17th. Wall Street Zen upgraded PAVmed from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Finally, Ascendiant Capital Markets lowered their price target on PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, June 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, PAVmed has an average rating of “Hold” and a consensus target price of $56.00.

PAVmed Trading Up 9.7%

The company’s fifty day simple moving average is $5.50 and its two-hundred day simple moving average is $7.89. The company has a market capitalization of $5.20 million, a price-to-earnings ratio of -0.14 and a beta of 0.54. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.70.

PAVmed (NASDAQ:PAVM) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.48). PAVmed had a negative net margin of 21,914.12% and a negative return on equity of 146.19%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.07 million. Research analysts forecast that PAVmed Inc. will post -2.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC grew its holdings in PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the quarter. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. 19.93% of the stock is owned by institutional investors.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.